Oncology &
Immunotherapy
Research Assays
Home to the world's largest commercial portfolio of mAb drug monitoring ELISA — including quantitative ADA and world's-only neutralizing antibody (nAb) assays for several biologics. KRIBIOLISA™ drug assays and GENLISA™ biomarker kits validated to US FDA guidelines across 16+ species, with 3,000+ peer-reviewed citations.
Immunogenicity Workflow.
Measures total drug concentration in serum or plasma using anti-idiotypic antibody capture — recognising the unique binding site of the therapeutic mAb, not its target. Drug-specific detection even in the presence of the endogenous target or concomitant medications. For a significant number of the 360+ drugs covered, we are the only commercial source globally.
Anti-drug antibodies (ADA) can neutralise biologics, alter their PK, and trigger adverse events. Krishgen's quantitative ADA uses validated reference standards to deliver true ng/mL or IU/mL results, enabling inter-study and inter-laboratory comparability required for regulatory submission packages.
An nAb specifically blocks the drug from binding its target — the clinically meaningful immune response that total ADA cannot distinguish. FDA and EMA increasingly require nAb data for biologic approvals. Developing these assays demands specialist anti-idiotypic reagents and competitive inhibition design. For several approved IO and oncology biologics, Krishgen's nAb assay is the world's only commercially available format.
All KRIBIOLISA™ drug assays are validated to a seven-point "Gold Ring" protocol aligned with US FDA bioassay guidelines: lot-to-lot consistency, dilutional linearity and recovery, intra- and inter-assay precision, stability, and sensitivity. Produced in an ISO 13485 and CDSCO-certified facility with Class 7/8 cleanrooms. For custom assay development, GLP-level studies, or matrix validation in NHP/rat/other species, contact services@krishgen.com.
Four Integrated Research Assay Areas
Krishgen's Oncology & Immunotherapy platform combines resources previously spread across cancer, immune checkpoint, immuno-oncology, and immunotherapy pages into a single hub for faster target discovery and assay selection.
KRIBIOLISA™ — The Only Portfolio Offering PK, Quantitative ADA & nAb Assays for Every Major IO Biologic
The products listed here show what the full workflow looks like in practice — drug PK quantitation, quantitative ADA, and nAb to drug — for two of the most widely used IO biologics. For trastuzumab, daratumumab, rituximab, blinatumomab, and several checkpoint inhibitors, the nAb assay is available only from Krishgen. Browse the drug class tables below for your biologic of interest, or contact us for the current nAb assay catalogue.
Browse All Drug Assays → Request nAb Assay ListBrowse by IO Target Category
Filter to your target class and find validated ELISA for biomarker quantitation across checkpoints, TME effectors, angiogenesis, metastasis, hypoxia, cancer stem cells, and cancer signalling.
The canonical IO checkpoint axis. Soluble PD-1 (sPD-1, KBBA50) and soluble PD-L1 (sPD-L1, KBBA52) serve as predictive biomarkers for response to pembrolizumab, nivolumab, atezolizumab, and durvalumab. PD-L2 (KBH4206) modulates airway immunity and some cancer subtypes.
View PD-1 ELISA →CTLA-4 competes with CD28 for CD80/CD86 binding, dampening early T cell priming in lymph nodes. Ipilimumab and tremelimumab target CTLA-4. CTLA-4 ELISA (KBH0277) measures soluble CTLA-4 in serum and plasma. Mouse reactivity available for pre-clinical syngeneic models.
View CTLA-4 ELISA →VISTA (PD-1H, B7-H5, KBH2153) suppresses T cell activation independent of PD-1/CTLA-4. B7-H4 (KBH6532) is overexpressed in breast, ovarian, and lung cancer. Both are emerging targets for next-generation checkpoint blockade. Human ELISA validated in serum and plasma.
View VISTA ELISA →TIM-3 (KBH5390) is expressed on exhausted T cells, DCs, and NK cells; its ligands include Galectin-9 (KBH2998), HMGB1, and Ceacam-1. Elevated sTIM-3 is associated with poor prognosis in AML, NSCLC, and HCC. Galectin-9 ELISA is available in Human, Mouse, and Rat.
View TIM-3 ELISA →TIM-1 (also known as KIM-1 / Kidney Injury Molecule-1) regulates Th2 cytokine production and serves as a renal injury biomarker as well as a target in some carcinomas. Available in Human, Mouse, Rat, Porcine, and Rabbit. Widely cited in renal cell carcinoma and Th1/Th2 balance studies.
View TIM-1 ELISA →BCMA is the primary target for multiple myeloma immunotherapy, targeted by belantamab mafodotin (ADC), daratumumab combinations, and bispecific antibodies (teclistamab, talquetamab). BCMA ELISA (KBH6650) measures soluble BCMA shed from malignant plasma cells. Available in Human and Mouse.
View BCMA ELISA →OX40 (CD134, KBH3356) and CD137 (4-1BB, KBH6343) are co-stimulatory receptors that promote T cell expansion, survival, and memory formation. Both are agonist antibody targets in IO. OX40 is especially relevant in Treg depletion within tumours. Available in Human and Mouse.
View OX40 ELISA →GITR (KBH6339) is upregulated on tumour-infiltrating Tregs and effector T cells, a target for anti-Treg therapy. HVEM (KBH6641) serves as both an inhibitory and activating ligand. BAFF (KBH1967) drives B cell survival and is relevant in B cell malignancies and CAR-B therapy research.
View GITR ELISA →VEGF (KB1155) is the master regulator of tumour angiogenesis — the primary target of bevacizumab, ramucirumab, and multi-kinase inhibitors. VEGFR2 (KBH4535) is the main signalling receptor on endothelial cells. Both are central to anti-angiogenic combination IO strategies. Available in 7+ species.
View VEGF ELISA →Granzyme B (KBH0899) and Perforin (KBH7989) are direct markers of CTL and NK cell cytotoxic activity. Elevated circulating Granzyme B correlates with immunotherapy efficacy across tumour types. Both ELISA are available in Human, Mouse, and Rat — essential for validating CAR-T, NK cell, and checkpoint therapy activity.
View Granzyme B ELISA →IFN-γ (KB1053) drives MHC-I upregulation and tumour immunogenicity. IL-6 (KBH8009) promotes Treg/Th17 imbalance and is implicated in cytokine release syndrome (CRS). TNF-α (KB1145) mediates direct tumour killing and ADCC potentiation. All available in Human, Mouse, Rat, and multiple additional species.
View IFN-γ ELISA →Arginase-1 (KBH4984), secreted by MDSCs and tumour-associated macrophages (TAMs), depletes L-arginine and suppresses T cell function. STAT3 (KBH0650) is activated downstream of IL-6 and drives tumour immune evasion. Both are key readouts for TME suppression and macrophage polarisation studies.
View Arginase-1 ELISA →CD73 (KBH5056) converts AMP to immunosuppressive adenosine in the TME, blunting T cell and NK cell function. Soluble CD73 is elevated in many solid tumours and correlates with poor prognosis. Multiple CD73-targeting antibodies (oleclumab, ulocuplumab) are in clinical development. Available in Human and Mouse.
View CD73 ELISA →LAG-3 (Lymphocyte Activation Gene-3) is expressed on exhausted CD4+ and CD8+ T cells and Tregs. It binds MHC-II and FGL1 to suppress T cell activation. Soluble LAG-3 is shed from activated lymphocytes and measurable in serum. Relatlimab (anti-LAG-3, combined with nivolumab as Opdualag) is the first approved dual checkpoint inhibitor — establishing LAG-3 as a validated clinical target in melanoma and beyond.
View LAG-3 ELISA →TIGIT (T cell Immunoreceptor with Ig and ITIM domains) competes with CD226 (DNAM-1) for binding to CD155 (PVR) and CD112 on tumour and APC surfaces, delivering a strong inhibitory signal to CD8+ T cells and NK cells. Anti-TIGIT antibodies (tiragolumab, vibostolimab) are in late-stage development across NSCLC, SCLC, and hepatocellular carcinoma, frequently in combination with PD-1 blockade.
View TIGIT ELISA →Epithelial-to-mesenchymal transition (EMT) is a key mechanism driving tumour invasion and metastasis. Loss of E-Cadherin (a cell-adhesion protein that maintains epithelial integrity) and gain of Vimentin (an intermediate filament protein characteristic of mesenchymal cells) are the canonical biomarker pair for EMT status. Soluble E-Cadherin fragments are detectable in serum and correlate with metastatic disease in breast, gastric, and colorectal cancers. Both ELISA available in Human.
View E-Cadherin ELISA →Matrix metalloproteinases MMP2 and MMP9 degrade collagen IV and other ECM components, enabling tumour cell invasion through the basement membrane. Elevated serum MMP2 and MMP9 are established biomarkers of metastatic potential across lung, breast, colorectal, and ovarian cancers. Both are also relevant readouts in angiogenesis research as VEGF-driven tumours upregulate MMP activity to remodel the vascular microenvironment. Available in Human, Mouse, and Rat.
View MMP2 ELISA →Hypoxia-inducible factor 1-alpha (HIF-1α) is the master transcriptional regulator of the tumour hypoxia response, driving expression of VEGF, GLUT1, PDK1, and other genes that enable tumour survival and immune evasion in low-oxygen environments. HIF-1α stabilisation in the TME promotes an immunosuppressive phenotype by upregulating PD-L1 on tumour cells and impairing CTL function. Elevated serum HIF-1α correlates with advanced disease stage and poor prognosis in NSCLC, RCC, and breast cancer.
View HIF-1α ELISA →Cancer stem cells (CSCs) are a subpopulation with self-renewal capacity, therapy resistance, and metastatic potential. ALDH1A1 (aldehyde dehydrogenase 1A1) is an intracellular detoxification enzyme and functional CSC marker across breast, lung, and colorectal cancers. CD44 is a cell surface glycoprotein upregulated on CSCs in most solid tumour types; elevated soluble CD44 correlates with metastatic disease. CD133 (Prominin-1) marks CSC populations in colorectal, glioblastoma, hepatocellular, and ovarian cancer and is associated with chemotherapy resistance. All three available as ELISA in Human.
View Cancer Stem Cell ELISA →Key IHC & ELISA Biomarkers by Tumour Type
Select a cancer type to explore the primary diagnostic and prognostic biomarkers used in IHC and ELISA-based research, mapped to available Krishgen assays.
Lung Cancer Biomarkers — NSCLC & SCLC
Lung cancer (NSCLC ~75% of cases) is the primary indication for anti-PD-1/PD-L1 therapy. PD-L1 IHC expression guides pembrolizumab first-line use. EGFR mutations (L858R, exon-19 del) define patients for TKI therapy. VEGF drives tumour angiogenesis. MET amplification is an emerging resistance mechanism and actionable target.
Breast Cancer Biomarkers — HR+, HER2+, TNBC
HER2 overexpression (~20–30% of breast cancers) is the primary biomarker for trastuzumab, pertuzumab, and T-DXd (trastuzumab deruxtecan) selection. Triple-negative breast cancer (TNBC) is the subtype most responsive to anti-PD-1/PD-L1 therapy. VEGF drives angiogenesis across subtypes. EGFR is frequently overexpressed in TNBC and inflammatory breast cancer.
Colorectal Cancer Biomarkers — CRC
EGFR is the primary therapeutic target in metastatic CRC (cetuximab, panitumumab — restricted to RAS wild-type). VEGF drives angiogenesis targeted by bevacizumab and ramucirumab. MSI-H/dMMR status defines the subset (~15%) responsive to pembrolizumab and nivolumab. KRAS mutation (G12C) is now targetable with sotorasib. IL-8 / CXCL8 promotes tumour-associated neutrophil recruitment.
Prostate Cancer Biomarkers — Localised & mCRPC
PSA remains the primary diagnostic marker but lacks specificity for aggressive disease. PSMA is the leading target for 177Lu-PSMA-617 RLT and next-generation imaging. In mCRPC, BCMA expression is being explored for bispecific Ab approaches. Immunotherapy faces challenges from a typically cold TME; combinations with CTLA-4 + PD-1 blockade show promise. IL-6 and STAT3 signalling drives castration resistance.
Ovarian Cancer Biomarkers — HGSC & Other Subtypes
CA-125 (MUC16) is the primary serum biomarker for ovarian cancer monitoring. PD-L1 expression is found in ~30–60% of ovarian tumors and correlates with CD8+ TIL density. VEGF-A is the therapeutic target of bevacizumab in the ICON7 and GOG-0218 trials. IL-6 drives the immunosuppressive ascites microenvironment. Emerging target: HE4 for early detection, combined with CA-125 in the ROMA algorithm.
Pancreatic Cancer Biomarkers — PDAC
Pancreatic ductal adenocarcinoma (PDAC) has one of the most immunosuppressive TMEs, dominated by desmoplastic stroma, immunosuppressive CAFs, MDSCs, and Tregs. VEGF drives extensive neo-angiogenesis. IL-6/STAT3 signalling promotes tumour cell survival. KRAS G12C and G12D mutations are now druggable. Mesothelin is an emerging CAR-T and ADC target. PD-1/PD-L1 monotherapy has limited efficacy; combination strategies with CD40 agonists, TGF-β blockade, or CXCR2 inhibition are in clinical trials.
Hematologic Malignancies — MM, DLBCL, AML, ALL
Multiple myeloma (MM) is driven by BCMA-positive malignant plasma cells — the primary target for belantamab mafodotin, teclistamab, and CAR-T (idecabtagene vicleucel, ciltacabtagene autoleucel). BAFF/APRIL promote B cell/plasma cell survival. In AML and ALL, TIM-3 and CD73 are overexpressed. Granzyme B and Perforin track CAR-T and BiTE activity. IL-6 underlies CRS in CAR-T therapy — critical to monitor.
KRIBIOLISA™ mAb Drug ELISA by Drug Class
360+ validated assays across all major oncology biologic classes — including 34+ ADC drug quantitation ELISA validated per ICH M10 guidelines. PK, Quantitative ADA, and nAb availability shown per drug. Click any block to expand. Contact info@krishgen.com for catalogue numbers and validation guides.
Checkpoint Inhibitors — Anti-PD-1 / Anti-PD-L1 / Anti-CTLA-4
Checkpoint inhibitors now cover 15+ tumour types. Krishgen holds PK, quantitative ADA, and nAb assays for all approved agents. The paired biomarker ELISA (sPD-1, sPD-L1, sCTLA-4) enables target engagement confirmation alongside drug PK. For pembrolizumab, nivolumab, and ipilimumab, the nAb assay is available only from Krishgen. Kits validated in human serum and plasma; NHP or other matrix validation available on request.
| Drug (Brand) | Target | Indication(s) | Drug PK Assay | Quantitative ADA | nAb to Drug | Biomarker ELISA |
|---|---|---|---|---|---|---|
| Pembrolizumab (Keytruda) | PD-1 | NSCLC, Melanoma, HNSCC, TNBC, dMMR | KBI1084 | Available | World's Only | KBBA50 • sPD-1 |
| Nivolumab (Opdivo) | PD-1 | NSCLC, Melanoma, RCC, HCC, Gastric | Available | Available | World's Only | KBBA50 • sPD-1 |
| Cemiplimab (Libtayo) | PD-1 | CSCC, BCC, NSCLC | Available | Available | Available | KBBA50 • sPD-1 |
| Atezolizumab (Tecentriq) | PD-L1 | NSCLC, TNBC, Urothelial, HCC | Available | Available | Available | KBBA52 • sPD-L1 |
| Durvalumab (Imfinzi) | PD-L1 | Stage III NSCLC, SCLC, Biliary | Available | Available | Available | KBBA52 • sPD-L1 |
| Avelumab (Bavencio) | PD-L1 | Merkel cell, Urothelial | Available | Available | Available | KBBA52 • sPD-L1 |
| Ipilimumab (Yervoy) | CTLA-4 | Melanoma, NSCLC, RCC (+ nivolumab) | Available | Available | World's Only | KBH0277 • sCTLA-4 |
| Tremelimumab (Imjudo) | CTLA-4 | NSCLC (+ durvalumab), HCC | Available | Available | Available | KBH0277 • sCTLA-4 |
Anti-HER2 / ErbB2 Therapies
HER2-targeted therapy spans mAbs, bispecific antibodies, and ADCs across breast, gastric, and now HER2-low tumours. The extensive biosimilar field for trastuzumab makes immunogenicity characterisation a high-volume research need — and the nAb to trastuzumab assay is available only from Krishgen. Serum HER2 ECD shedding can be monitored as a response/resistance biomarker alongside drug PK.
| Drug (Brand) | Class | Indication(s) | Drug PK Assay | Quantitative ADA | nAb to Drug |
|---|---|---|---|---|---|
| Trastuzumab (Herceptin / biosimilars) | Anti-HER2 mAb | HER2+ Breast, Gastric/GEJ | Available | Available | World's Only |
| Pertuzumab (Perjeta) | Anti-HER2 mAb | HER2+ Breast (+ trastuzumab) | Available | Available | Available |
| T-DM1 / Ado-trastuzumab (Kadcyla) | ADC | HER2+ Breast (2nd line) | Available | Available | Available |
| T-DXd / Trastuzumab deruxtecan (Enhertu) | ADC | HER2+ / HER2-low Breast, NSCLC, Gastric | Available | Available | Available |
| Margetuximab (Margenza) | Fc-optimised anti-HER2 mAb | HER2+ Breast (3rd line+) | Available | Available | Contact us |
Anti-VEGF / Anti-Angiogenic Therapies
Anti-VEGF therapy inhibits tumour neovascularisation across multiple solid tumour types. Bevacizumab's active biosimilar development makes immunogenicity testing — including nAb assays — a high-priority area. VEGF ELISA (KB1155) and VEGFR2 ELISA (KBH4535) enable paired target-engagement monitoring alongside drug PK; VEGF is available in 7+ species for pre-clinical models.
| Drug (Brand) | Target | Indication(s) | Drug PK Assay | Quantitative ADA | nAb to Drug | Biomarker ELISA |
|---|---|---|---|---|---|---|
| Bevacizumab (Avastin / biosimilars) | VEGF-A | CRC, NSCLC, Ovarian, Cervical, GBM | Available | Available | World's Only | KB1155 • VEGF |
| Ramucirumab (Cyramza) | VEGFR2 | Gastric, NSCLC, CRC, HCC | Available | Available | Available | KBH4535 • VEGFR2 |
| Aflibercept (Zaltrap) | VEGF-A/B, PlGF | mCRC (+ FOLFIRI) | Available | Available | Available | KB1155 • VEGF |
BCMA / CD38 / SLAMF7 — Multiple Myeloma Therapies
The multiple myeloma space has seen rapid biologic adoption across CD38, BCMA, and SLAMF7 targets. For daratumumab — now used in nearly every line of myeloma therapy — the nAb assay is available only from Krishgen. Soluble BCMA (sBCMA, KBH6650) is a validated pharmacodynamic biomarker that drops with effective anti-BCMA therapy and rises at relapse.
| Drug (Brand) | Target | Class | Drug PK Assay | Quantitative ADA | nAb to Drug | Biomarker ELISA |
|---|---|---|---|---|---|---|
| Daratumumab (Darzalex) | CD38 | Anti-CD38 mAb | Available | Available | World's Only | CD38 ELISA • Contact us |
| Isatuximab (Sarclisa) | CD38 | Anti-CD38 mAb | Available | Available | Available | CD38 ELISA • Contact us |
| Belantamab mafodotin (Blenrep) | BCMA | ADC | Available | Available | Available | KBH6650 • sBCMA |
| Teclistamab (Tecvayli) | BCMA × CD3 | Bispecific Ab | Available | Available | Available | KBH6650 • sBCMA |
| Elotuzumab (Empliciti) | SLAMF7/CS1 | Anti-SLAMF7 mAb | Available | Available | Available | SLAMF7 ELISA • Contact us |
Bispecific Antibodies — T Cell Engagers & Dual Checkpoint
Bispecific antibodies are the fastest-growing class in oncology development. Krishgen's 40+ bispecific drug assays include nAb assays for several T cell-engaging agents — blinatumomab and mosunetuzumab available only from Krishgen. Granzyme B (KBH0899) and IL-6 (KBH8009) serve as pharmacodynamic and CRS safety biomarkers for CD3-engaging agents respectively. Krishgen's bispecific Ab ELISA portfolio was recognised with a CiteAb 2023 Innovation Award — Highly Commended, the only ELISA supplier acknowledged in this category.
| Drug (Brand) | Targets | Indication | Drug PK Assay | Quantitative ADA | nAb to Drug |
|---|---|---|---|---|---|
| Blinatumomab (Blincyto) | CD19 × CD3 | B-ALL, B-NHL | Available | Available | World's Only |
| Amivantamab (Rybrevant) | EGFR × MET | NSCLC (EGFR exon 20 ins) | Available | Available | Available |
| Mosunetuzumab (Lunsumio) | CD20 × CD3 | Follicular lymphoma | Available | Available | World's Only |
| Glofitamab (Columvi) | CD20 × CD3 | DLBCL, FL | Available | Available | Available |
| Talquetamab (Talvey) | GPRC5D × CD3 | Multiple Myeloma | Available | Available | Available |
Anti-EGFR & Other Targeted Oncology Biologics
Anti-EGFR antibodies cetuximab and panitumumab are established in RAS wild-type mCRC and HNSCC. Rituximab has a large and active biosimilar field — the nAb to rituximab assay is available only from Krishgen. CD40 agonist antibodies in clinical development are supported by CD40 biomarker ELISA (KBH11145) across 6 species.
| Drug (Brand) | Target | Indication(s) | Drug PK Assay | Quantitative ADA | nAb to Drug | Biomarker ELISA |
|---|---|---|---|---|---|---|
| Cetuximab (Erbitux) | EGFR | RAS WT CRC, HNSCC | Available | Available | Available | EGFR ELISA • Contact us |
| Panitumumab (Vectibix) | EGFR | RAS WT mCRC | Available | Available | Available | EGFR ELISA • Contact us |
| Rituximab (MabThera / biosimilars) | CD20 | DLBCL, FL, CLL, RA | Available | Available | World's Only | CD20 ELISA • Contact us |
| Denosumab (Xgeva / Prolia) | RANKL | Bone metastases, GCTB, Osteoporosis | Available | Available | Available | RANKL ELISA • Contact us |
| CD40 Agonists (investigational) | CD40 | PDAC, solid tumours (clinical trials) | Available | Available | Contact us | KBH11145 • CD40 |
Antibody-Drug Conjugate (ADC) Drug Quantitation ELISA
ADCs combine a tumour-targeting antibody with a cytotoxic payload via a chemical linker. Accurate PK quantitation is technically challenging — assays must measure total ADC (all drug-to-antibody ratio species), intact ADC, or unconjugated antibody depending on the study endpoint. Krishgen's KRIBIOLISA™ ADC ELISA are validated per ICH M10 bioassay guidelines, using lyophilized reference standards calibrated against WHO/NIBSC standards or commercially sourced innovator drug. Break-apart wells, CV <10%, and recovery 85–120% across serum and EDTA/heparin/citrate plasma.
| ADC Drug | Antibody Target | Payload | Primary Indication(s) | PK Assay |
|---|---|---|---|---|
| Trastuzumab emtansine / T-DM1 (Kadcyla) | HER2 | DM1 (maytansinoid) | HER2+ Breast (2nd line) | Available |
| Sacituzumab govitecan (Trodelvy) | TROP-2 | SN-38 (irinotecan metabolite) | TNBC, Urothelial | Available |
| Enfortumab vedotin (Padcev) | Nectin-4 | MMAE (auristatin) | Urothelial carcinoma | Available |
| Polatuzumab vedotin (Polivy) | CD79b | MMAE (auristatin) | DLBCL | Available |
| Belantamab mafodotin (Blenrep) | BCMA | MMAF (auristatin) | Multiple Myeloma | Available |
| Gemtuzumab ozogamicin (Mylotarg) | CD33 | Calicheamicin | AML | Available |
| Brentuximab vedotin (Adcetris) — Intact | CD30 | MMAE (auristatin) | Hodgkin lymphoma, ALCL | Available |
| Tisotumab vedotin (Tivdak) | Tissue Factor | MMAE (auristatin) | Cervical cancer | Available |
| Patritumab deruxtecan (HER3-DXd) | HER3 | DXd (topoisomerase I inhibitor) | NSCLC (EGFR-mutated) | Available |
| Disitamab vedotin (RC48) | HER2 | MMAE (auristatin) | HER2+ Gastric, Breast | Available |
| Ladiratuzumab vedotin | LIV-1 (ZIP6) | MMAE (auristatin) | Breast cancer (clinical trials) | Available |
| Denintuzumab mafodotin | CD19 | MMAF (auristatin) | B-ALL, DLBCL (clinical trials) | Available |
| Vorsetuzumab mafodotin | CD70 | MMAF (auristatin) | RCC, DLBCL (clinical trials) | Available |
| Samrotamab vedotin | LRRC15 | MMAE (auristatin) | Sarcoma, solid tumours | Available |
| Telisotuzumab vedotin | c-Met (HGF-R) | MMAE (auristatin) | NSCLC (c-Met overexpressing) | Available |
Pre-Clinical & Translational Species Support
Core IO and cancer biomarker ELISA are available in Human plus key pre-clinical species. Mouse and Rat kits are validated for syngeneic tumour models and xenograft studies. Contact us to validate in any additional matrix.
How to Select the Right Assay
Three simple steps to identify your optimal ELISA — whether profiling a TME cytokine in a pre-clinical model, monitoring a checkpoint biomarker in patient serum, or validating PK of a bispecific antibody.
What is your experimental goal? Characterise the TME of a syngeneic model? Profile checkpoint expression in patient cohort samples? Monitor drug PK in a Phase I study?
Browse by target class above or use the filter buttons. Confirm your species (Human, Mouse, Rat, NHP) and matrix (serum, plasma, cell culture supernatant, tumour lysate). Contact us for matrix-specific validation data.
Request our detailed validation guide (dilutional linearity, recovery, precision, specificity). For large lot requirements or custom matrix validation, our technical team can optimise any kit to your specific study design.
ISO 13485 Certified. CiteAb Innovation Award. 3,000+ Citations.
Krishgen is a dedicated ELISA manufacturer — not a distributor of third-party kits. Production runs in ISO 13485 and CDSCO-certified Class 7/8 cleanrooms in Mumbai and California, with automated plate-coating lines and strict inter-batch QC. Our bispecific antibody drug ELISA portfolio received a CiteAb 2023 Innovation Award — Highly Commended, recognising the depth and novelty of our KRIBIOLISA™ bsAb assay range. Our proprietary in-house blockers, buffers, and diluents are optimised for each assay class, delivering CV<10% and 80–120% recovery across validated matrices.
Every kit — biomarker ELISA or KRIBIOLISA™ drug assay — is built on well-validated, high-quality monoclonal antibodies, including anti-idiotypic antibodies developed in-house for drug-specific capture. This reagent depth is why we can offer a three-assay workflow (PK / ADA / nAb) that competitors cannot replicate.
Krishgen assays have been cited in 3,000+ peer-reviewed publications in journals including Cancer Research, Journal of Immunology, Clinical Cancer Research, and Annals of Oncology — providing the independent validation that grant reviewers and journal editors expect. For high-throughput studies, Genbulk™ packs reduce per-sample cost at scale.
Frequently Asked Questions
Need Something We Don't List?
Krishgen's in-house anti-idiotypic antibody development capability means we can build new assays to order. Whether you need a drug assay for a pipeline biologic, validation in an unusual matrix, or a novel biomarker ELISA for a target not yet in our catalogue — our custom services team can help.
Can't Find Your Target?
Krishgen manufactures 20,000+ ELISA across 10+ species. Our technical team can help identify the right assay — or custom-develop one for your specific target, species, or study design.
